Evidence map›Paper›PMID 31898234›Full record

ReviewAdvances in experimental medicine and biology2020

Cullin-RING E3 Ubiquitin Ligase 7 in Growth Control and Cancer.

Zhen-Qiang Pan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. More Than Just Cleaning: Ubiquitin-Mediated Proteolysis in Fungal Pathogenesis.Frontiers in cellular and infection microbiology · 2021
    Review
  8. Article
  9. Article
  10. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020
    Review
  11. Targeting ERK-Hippo Interplay in Cancer Therapy.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Zhen-Qiang PanDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. zhen-qiang.pan@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

Modulate Cullin-RING E3 ubiquitin ligases by small molecule agentsR01CA251425 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DEVITA, ROBERT J, PAN, ZHEN-QIANG · 2020 to 2024
$3.5M
Discover Small Molecule Chemical Probes to Modulate RING-type E3 Ubiquitin LigasesR01GM122751 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAN, ZHEN-QIANG · 2017 to 2019
$1.4M
NCI NIH HHS R01 CA251425NIGMS NIH HHS R01 GM122751
6 · The paper itself

Abstract

CRL7

Indexed as

AnimalsCarrier ProteinsCell ProliferationCullin ProteinsCytoskeletal ProteinsF-Box ProteinsHumansNeoplasmsProteolysisUbiquitinCarrier ProteinsCCDC8 protein, humanCUL7 protein, humanCullin ProteinsCytoskeletal ProteinsF-Box ProteinsOBSL1 protein, humanUbiquitin3-M diseaseCullin 7E3 ubiquitin ligaseGrowth signaling

Identifiers

PMID31898234
PMCPMC8343956
OpenAlexW2997198498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.